King Pharmaceuticals Loses Rehearing Bid
King Pharmaceuticals, Inc. revealed Monday that a federal appeals court has nixed its bid for a rehearing in a patent dispute over its top-selling hypertension medicine....To view the full article, register now.
Already a subscriber? Click here to view full article